Healthcare in Brazil faces access and integration challenges

In Brazil, the pharmaceutical industry faces challenges in ensuring that high-complexity treatments for rare diseases, cancer, and autoimmune conditions reach patients effectively. While innovation continues to expand treatment possibilities, access is often hindered by regulatory hurdles, pricing, and logistical complexities. Fernando Kutova of Expo-Hospital Brasil emphasizes that integrated collaboration between manufacturers, hospitals, distributors, and regulators is essential to prevent innovation from remaining inaccessible.

Simultaneously, new data from Funcional highlights the intersection of mental and physical health. An analysis of the Benefício Farmácia database reveals that 22.8% of antidepressant users also manage chronic conditions, and 35.7% use medications from two or more different therapeutic classes. Medical director Ricardo Moraes notes that this coexistence requires an integrated care approach to improve therapeutic adherence. Research suggests that patients with depression may face a 76% higher likelihood of failing to adhere to treatments for chronic diseases, which can impact both individual quality of life and broader economic productivity.